---
title: "Prime Medicine | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 1.154 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295104487.md"
datetime: "2026-08-06T12:04:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295104487.md)
  - [en](https://longbridge.com/en/news/295104487.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295104487.md)
---

# Prime Medicine | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 1.154 M

Revenue: As of FY2026 Q2, the actual value is USD 1.154 M, beating the estimate of USD 1.105 M.

EPS: As of FY2026 Q2, the actual value is USD -0.24.

EBIT: As of FY2026 Q2, the actual value is USD -42.5 M.

#### Cash Position

Prime Medicine, Inc. reported cash, cash equivalents, investments, and restricted cash of $108.8 million as of June 30, 2026, a decrease from $191.4 million as of December 31, 2025. Specifically, cash, cash equivalents, and investments were $95,071 thousand on June 30, 2026, down from $177,680 thousand on December 31, 2025.

#### Revenue

Collaboration revenue — related party was $1,154 thousand for the three months ended June 30, 2026, an increase from $1,115 thousand for the same period in 2025.

#### Operating Expenses

Research and Development (R&D) expenses decreased to $33,397 thousand for the three months ended June 30, 2026, from $41,375 thousand in the prior year period. General and Administrative (G&A) expenses also decreased to $11,042 thousand for the three months ended June 30, 2026, from $13,117 thousand in the same period of 2025. Total operating expenses were $44,439 thousand for the three months ended June 30, 2026, down from $54,492 thousand for the three months ended June 30, 2025.

#### Loss from Operations

Loss from operations for the three months ended June 30, 2026, was - $43,285 thousand, an improvement from - $53,377 thousand for the three months ended June 30, 2025.

#### Other Income, Net

Total other income, net, increased to $1,176 thousand for the three months ended June 30, 2026, compared to $786 thousand for the same period in 2025. This included interest income of $788 thousand (versus $743 thousand in 2025) and accretion (amortization) of investments of $333 thousand (versus $530 thousand in 2025). The change in fair value of short-term investment — related party was $0 thousand in Q2 2026, compared to - $505 thousand in Q2 2025.

#### Net Loss

Net loss attributable to common stockholders for the three months ended June 30, 2026, was - $42,109 thousand, an improvement from - $52,591 thousand for the three months ended June 30, 2025.

#### Balance Sheet Data

Total assets as of June 30, 2026, were $249,040 thousand, down from $342,733 thousand as of December 31, 2025. Total liabilities as of June 30, 2026, were $209,231 thousand, down from $221,865 thousand as of December 31, 2025. Total stockholders’ equity as of June 30, 2026, was $39,809 thousand, down from $120,868 thousand as of December 31, 2025.

#### Operational Highlights and Pipeline Progress

Prime Medicine, Inc. received IND and CTA clearances in the United States and New Zealand for PM577a in Wilson disease, with initial clinical data expected in 2027. The company achieved a favorable arbitration resolution with Beam Therapeutics, affirming its rights to PM647 in Alpha-1 Antitrypsin Deficiency, with an IND and/or CTA submission expected in Q3 2026 and initial clinical data in 2027. PM359 for Chronic Granulomatous Disease was granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA, with a Biologics License Application (BLA) submission targeted for the first half of 2027.

#### Financial Guidance

Prime Medicine, Inc. expects its cash, cash equivalents, and investments as of June 30, 2026, to fund its operating expenses and capital expenditure requirements into 2027.

### Related Stocks

- [PRME.US](https://longbridge.com/en/quote/PRME.US.md)

## Related News & Research

- [ESS Tech reschedules Q2 2026 results conference call to Tuesday evening](https://longbridge.com/en/news/295407778.md)
- [Can Gold Make a New High in 2026?](https://longbridge.com/en/news/295569739.md)
- [REG - UIL Limited UIL Finance Ltd - Purchase of 2026 ZDP Shares](https://longbridge.com/en/news/295955673.md)
- [Unifique approves Q2 2026 interim financial report](https://longbridge.com/en/news/295711035.md)
- [Diageo announces BRL 0.32 per unit distribution for Q3 2026](https://longbridge.com/en/news/295964479.md)